HIV-Neutralizing Polypeptides: A Novel Use for Platelet Factor 4 or Its Derivatives

The subject invention describes the method for using Platelet Factor 4 (PF4), also called CXCL4, to inhibit HIV viral entry by blocking GP120 independent of HIV receptor. It also demonstrates that the active polypeptide fragment(s) of PF-4 could be used to identify potential peptide mimics or small molecules that could be used to inhibit HIV infection. PF4 and/or its derivatives may be developed as a systemic therapy or preventive measure using topical applications, such as microbicides. In addition, CXCL4 serum/plasma testing could be used as a clinical marker of HIV disease status to predict/monitor the efficacy of treatment and determine the prognosis of a subject with HIV infection.

Potential Commercial Applications: Competitive Advantages:
  • Treatment and prevention of HIV-1 infection.
  • Topical application as microbicides.
  • A vaccine adjuvant to boost the vaccine efficacy.
  • A clinical marker of HIV disease status or to predict/monitor the efficacy of treatment or vaccines.
  • A new HIV-1 inhibitory molecule that acts through a new inhibitory mechanism.
  • Any potential derivative or mimicking compound would be unique and have the advantage of hitting a previously unrecognized molecular target in the HIV life cycle.

Paolo Lusso (NIAID)
David Auerbach (NIAID)

Intellectual Property:
US Application No. 61/649,150

Licensing Contact:
Sally Hu , Ph.D., M.B.A.
NIH Office of Technology Transfer
Phone: 301-435-5606

OTT Reference No: E-140-2012/0

Updated: Apr-04-2013